Clinical trial · Interventional
Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
A Pilot, Feasibility Study of Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
NCT06172283CI-TRIAL-00109057recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patients receiving androgen deprivation therapy. Study feasibility measures will include enrollment rate, drop-out rate and compliance with diet measured by self-reports.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intermittent Fasting | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intermittent Fasting
- description
- Patients will undergo 16h periods of fasting everyday. Optionally, patients will be offered to undergo a plant-based diet consisting of 20% plant based protein, 50% carbohydrates, and 30% fat for the duration of the study.
- interventionNames
- Other: Intermittent Fasting
Primary outcomes (2)
- measure
- Enrollment rate
- timeFrame
- 3 years
- description
- Feasibility of intermittent fasting (with the option of a plant-enriched diet) in prostate cancer patients receiving androgen deprivation therapy
- measure
- Drop-out rate
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * In order to be eligible for participation in this trial, the subject must: * Be willing and able to provide written informed consent for the trial. * Be male at birth and least 18 years of age on day of signing informed consent. * Have measurable prostate cancer disease and be eligible for androgen deprivation therapy. * Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. * Demonstrate adequate organ function (all screening labs should be performed within 10 days of treatment initiation). * Subjects have archival tumor tissue available or are willing to undergo a baseline biopsy prior to treatment. * Subjects must have a life expectancy of at least 6 months. Exclusion Criteria: * Has an ECOG performance of 2 or higher. * Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the beginning of the treatment. * Has a known additional malignancy that is progressing or requires active treatment. * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Has a known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT/MRI imaging * Has any other medical intervention or condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives. * Is not willing and able to provide written informed consent for the trial.
References
Publications (0)
Data not yet available
No reference posted for this study.